BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 24462714)

  • 1. Pathway-based analysis of the hidden genetic heterogeneities in cancers.
    Zhao X; Zhong S; Zuo X; Lin M; Qin J; Luan Y; Zhang N; Liang Y; Rao S
    Genomics Proteomics Bioinformatics; 2014 Feb; 12(1):31-8. PubMed ID: 24462714
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Unravelling the hidden heterogeneities of diffuse large B-cell lymphoma based on coupled two-way clustering.
    Zhang W; Li L; Li X; Jiang W; Huo J; Wang Y; Lin M; Rao S
    BMC Genomics; 2007 Sep; 8():332. PubMed ID: 17888167
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Peeling off the hidden genetic heterogeneities of cancers based on disease-relevant functional modules.
    Xu JZ; Guo Z; Zhang M; Li X; Li YJ; Rao SQ
    Mol Med; 2006; 12(1-3):25-33. PubMed ID: 16838067
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Analysis of diffuse large B-cell lymphoma heterogeneity based on coupled two-way clustering].
    Li L; Li X; Chen YH; Guo Z; Jiang W; Zhagn RJ; Rao SQ
    Yi Chuan; 2006 Sep; 28(9):1129-34. PubMed ID: 16963424
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Unraveling the hidden heterogeneities of breast cancer based on functional miRNA cluster.
    Li L; Liu C; Wang F; Miao W; Zhang J; Kang Z; Chen Y; Peng L
    PLoS One; 2014; 9(1):e87601. PubMed ID: 24498150
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Molecular profiling of diffuse large B-cell lymphoma identifies robust subtypes including one characterized by host inflammatory response.
    Monti S; Savage KJ; Kutok JL; Feuerhake F; Kurtin P; Mihm M; Wu B; Pasqualucci L; Neuberg D; Aguiar RC; Dal Cin P; Ladd C; Pinkus GS; Salles G; Harris NL; Dalla-Favera R; Habermann TM; Aster JC; Golub TR; Shipp MA
    Blood; 2005 Mar; 105(5):1851-61. PubMed ID: 15550490
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Discovery and validation of immune-associated long non-coding RNA biomarkers associated with clinically molecular subtype and prognosis in diffuse large B cell lymphoma.
    Zhou M; Zhao H; Xu W; Bao S; Cheng L; Sun J
    Mol Cancer; 2017 Jan; 16(1):16. PubMed ID: 28103885
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Molecular subtypes of diffuse large B-cell lymphoma arise by distinct genetic pathways.
    Lenz G; Wright GW; Emre NC; Kohlhammer H; Dave SS; Davis RE; Carty S; Lam LT; Shaffer AL; Xiao W; Powell J; Rosenwald A; Ott G; Muller-Hermelink HK; Gascoyne RD; Connors JM; Campo E; Jaffe ES; Delabie J; Smeland EB; Rimsza LM; Fisher RI; Weisenburger DD; Chan WC; Staudt LM
    Proc Natl Acad Sci U S A; 2008 Sep; 105(36):13520-5. PubMed ID: 18765795
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Diffuse large B-cell lymphoma.
    Li S; Young KH; Medeiros LJ
    Pathology; 2018 Jan; 50(1):74-87. PubMed ID: 29167021
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Biological and Clinical Relevance of Associated Genomic Alterations in MYD88 L265P and non-L265P-Mutated Diffuse Large B-Cell Lymphoma: Analysis of 361 Cases.
    Dubois S; Viailly PJ; Bohers E; Bertrand P; Ruminy P; Marchand V; Maingonnat C; Mareschal S; Picquenot JM; Penther D; Jais JP; Tesson B; Peyrouze P; Figeac M; Desmots F; Fest T; Haioun C; Lamy T; Copie-Bergman C; Fabiani B; Delarue R; Peyrade F; André M; Ketterer N; Leroy K; Salles G; Molina TJ; Tilly H; Jardin F
    Clin Cancer Res; 2017 May; 23(9):2232-2244. PubMed ID: 27923841
    [No Abstract]   [Full Text] [Related]  

  • 11. Intra-tumour heterogeneity of diffuse large B-cell lymphoma involves the induction of diversified stroma-tumour interfaces.
    Sangaletti S; Iannelli F; Zanardi F; Cancila V; Portararo P; Botti L; Vacca D; Chiodoni C; Di Napoli A; Valenti C; Rizzello C; Vegliante MC; Pisati F; Gulino A; Ponzoni M; Colombo MP; Tripodo C
    EBioMedicine; 2020 Nov; 61():103055. PubMed ID: 33096480
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Diffuse Large B-Cell Lymphoma and High-Grade B-Cell Lymphoma: Genetic Classification and Its Implications for Prognosis and Treatment.
    Crombie JL; Armand P
    Hematol Oncol Clin North Am; 2019 Aug; 33(4):575-585. PubMed ID: 31229155
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A 9 series microRNA signature differentiates between germinal centre and activated B-cell-like diffuse large B-cell lymphoma cell lines.
    Culpin RE; Proctor SJ; Angus B; Crosier S; Anderson JJ; Mainou-Fowler T
    Int J Oncol; 2010 Aug; 37(2):367-76. PubMed ID: 20596664
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A Probabilistic Classification Tool for Genetic Subtypes of Diffuse Large B Cell Lymphoma with Therapeutic Implications.
    Wright GW; Huang DW; Phelan JD; Coulibaly ZA; Roulland S; Young RM; Wang JQ; Schmitz R; Morin RD; Tang J; Jiang A; Bagaev A; Plotnikova O; Kotlov N; Johnson CA; Wilson WH; Scott DW; Staudt LM
    Cancer Cell; 2020 Apr; 37(4):551-568.e14. PubMed ID: 32289277
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Constitutive nuclear factor kappaB activity is required for survival of activated B cell-like diffuse large B cell lymphoma cells.
    Davis RE; Brown KD; Siebenlist U; Staudt LM
    J Exp Med; 2001 Dec; 194(12):1861-74. PubMed ID: 11748286
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Genomic profiling using array comparative genomic hybridization define distinct subtypes of diffuse large B-cell lymphoma: a review of the literature.
    Tirado CA; Chen W; García R; Kohlman KA; Rao N
    J Hematol Oncol; 2012 Sep; 5():54. PubMed ID: 22967872
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Molecular profiling in diffuse large B-cell lymphoma: why so many types of subtypes?
    Morin RD; Arthur SE; Hodson DJ
    Br J Haematol; 2022 Feb; 196(4):814-829. PubMed ID: 34467527
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Diffuse large B-cell lymphoma patient-derived xenograft models capture the molecular and biological heterogeneity of the disease.
    Chapuy B; Cheng H; Watahiki A; Ducar MD; Tan Y; Chen L; Roemer MG; Ouyang J; Christie AL; Zhang L; Gusenleitner D; Abo RP; Farinha P; von Bonin F; Thorner AR; Sun HH; Gascoyne RD; Pinkus GS; van Hummelen P; Wulf GG; Aster JC; Weinstock DM; Monti S; Rodig SJ; Wang Y; Shipp MA
    Blood; 2016 May; 127(18):2203-13. PubMed ID: 26773040
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Differential efficacy of bortezomib plus chemotherapy within molecular subtypes of diffuse large B-cell lymphoma.
    Dunleavy K; Pittaluga S; Czuczman MS; Dave SS; Wright G; Grant N; Shovlin M; Jaffe ES; Janik JE; Staudt LM; Wilson WH
    Blood; 2009 Jun; 113(24):6069-76. PubMed ID: 19380866
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Molecular heterogeneity of diffuse large B-cell lymphoma: implications for disease management and prognosis.
    Rossi D; Gaidano G
    Hematology; 2002 Aug; 7(4):239-52. PubMed ID: 14972786
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.